Vimarsana
Biggest News Aggregation in the World

Page 20 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

JS Global Wins Five Awards at Institutional Investor's "2022 All-Asia Executive Team" - Vimarsana News

JS Global Wins Five Awards at Institutional Investor's "2022 All-Asia Executive Team"

HONG KONG, June 27, 2022 /PRNewswire/ -- JS Global Lifestyle Company Limited (HKEX stock code: 1691) ('JS Global' or the 'Company') has been award...

Xiaomi Wins Institutional Investor's Asia Executive Team Awards for the Fourth Consecutive Year - Vimarsana News

Xiaomi Wins Institutional Investor's Asia Executive Team Awards for the Fourth Consecutive Year

BEIJING and HONG KONG, June 23, 2022 /PRNewswire/ --Xiaomi Corporation ("Xiaomi" or the "Group"; stock code:1810), a consumer electronics and smart manufacturing company with smartphones and smart hardware connected by an Internet of Things (IoT) platform at its core, has been awarded by Institutional Investor, a renowned international financial magazine, in multiple categories of Asia Pacific (Ex-Japan) Executive Team Awards for the fourth consecutive year. In Technology Hardware sector, Xiaomi wins five category awards in "2022 Asia Pacific(Ex-Japan) Executive Team&q...

Junshi Biosciences Highlights Pipeline Advances in - Vimarsana News

Junshi Biosciences Highlights Pipeline Advances in

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors ...

Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022 - Vimarsana News

Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors --Toripalimab continues to demonstrate synergy as the

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022 - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

Investegate announcements from Junshi Biosciences, Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022